Our purpose

At NRG Therapeutics, we are driven by a clear purpose: to translate breakthrough mitochondrial science into life-enhancing new medicines for people living with devastating neurodegenerative diseases.

We are an innovative clinical-stage neuroscience company pioneering disease-modifying medicines designed to slow or halt neurodegeneration in amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s.

Our approach is focused on understanding the causes of mitochondrial dysfunction, a core contributor to neuronal stress, neuroinflammation and neurodegeneration. By restoring mitochondrial integrity and energy and protecting vulnerable neurons we aim to address the underlying drivers of disease — not just the symptoms.

Science

Our pipeline

Our lead clinical asset is built on first‑in‑class chemistry and a new understanding of the role of NLRX1 in modulating mitochondrial function.

We are developing a pipeline of CNS‑penetrant, oral small molecules designed to bind NLRX1 and inhibit the mitochondrial permeability transition pore (mPTP) — a key contributor to the neuroinflammatory and neurodegenerative pathology seen in ALS and Parkinson’s.

Pipeline

Team

NRG is a private company based in the UK and brings together a team of experienced drug discoverers, neuroscientists and biotech leaders.

Supported by world-leading scientific advisors and expert drug development partners, and backed by leading healthcare investors, and not-for-profit disease foundations — we are all united by the belief that restoring mitochondrial health can transform lives and reduce the impact of neurodegenerative disease.

Team

“

The strength and breadth of NRG’s preclinical data gives us real confidence that NRG’s approach could halt or significantly slow disease progression across multiple neurodegenerative diseases. We are excited that NRG’s lead clinical asset has the potential to be the first disease-modifying therapeutic for sporadic ALS and dementia indications such as Parkinson’s.”

Investor

Investors

,

Partnering strategy

Our goal is to progress our novel disease-modifying clinical assets through proof-of-concept clinical trials for late-stage development and commercialization by global pharma partners.